allogeneic transplant in multiple myeloma: who should receive it and the future of transplant
Published 7 years ago • 360 plays • Length 8:29Download video MP4
Download video MP3
Similar videos
-
1:33
the role of allogeneic transplantation in patients with multiple myeloma
-
1:56
current investigations in the use of allogeneic transplant in the treatment of myeloma
-
3:29
what are the challenges of allogeneic stem cell transplant in myeloma?
-
4:13
when is allogeneic transplant the right answer for mm?
-
6:23
how long will i live with multiple myeloma and is there a cure?
-
3:38
what is the difference between autologous and allogeneic transplant?
-
5:30
why is myeloma hard to treat? what is meant by a signaling pathway?
-
1:04
the changing role of autosct in the treatment of multiple myeloma in the era of novel agents
-
2:49
the importance of timing in autologous transplantation for multiple myeloma
-
1:30
exploring the role of upfront autosct in multiple myeloma
-
1:03
allogeneic transplant in high-risk mm groups
-
1:53
transplantation for consolidation in multiple myeloma
-
1:53
the future of multiple myeloma treatment
-
2:39
a look into the future of multiple myeloma treatment: t-cell redirecting therapies vs autohsct
-
3:00
moving away from allosct to cellular therapy in multiple myeloma: current and future outlooks
-
3:12
allogeneic hsct in patients with high-risk myeloma
-
4:33
cmwp & ebmt report: allogeneic hct outcomes in myeloma patients on renal replacement
-
1:54
the future of multiple myeloma treatment
-
3:23
the role of allo-transplant for patients with all
-
3:44
is double autologous transplantation in multiple myeloma superior in the age of new agents?
-
1:55
mm: when is allogeneic transplant is the right answer?